Accenture Invests in Good Chemistry Company to Help Drive Quantum Computing Advancements in Material
Summary
This brings a competitive advantage to clients and can change pharmaceutical drug discovery and more.” According to the Accenture Technology Vision 2022, 69% of global executives say quantum computing will have a breakthrough or transformational positive impact on their organizations in the future. Quantum is the pinnacle of next generation problem solving and Accenture and Biogen collaborated with 1QBit already to accelerate drug discovery, developing a proof of concept that validated a quantum-computing molecule comparison approach and building an enterprise-ready, quantum-enabled application with transparent processes that generates molecular comparison results with deeper insights about shared traits. With Accenture’s support and collaboration, we will be able to explore the vastness of chemical space and enable rational materials design at scale.” Carl Dukatz, Accenture’s global quantum computing lead said, “By building on and extending our relationship with 1QBit to the newly formed Good Chemistry Company, we are demonstrating our ongoing commitment to accelerating quantum computing innovation. We recognize the potential of arming our clients with the next generation of chemistry, material science, and structural design.” Good Chemistry Company is the latest organization to join Accenture Ventures’ Project Spotlight, an engagement and investment program that connects emerging technology software startups with the Global 2000 to fill strategic innovation gaps. Project Spotlight offers extensive access to Accenture’s domain expertise and its enterprise clients, helping startups harness human creativity and deliver on the promise of their technology.